Basal Cell Carcinoma: From the Molecular Understanding of the Pathogenesis to Targeted Therapy of Progressive Disease

Table 1

Current and future HH pathway inhibitors.

SMO-Inhibitors	Ongoing trials	Indication
GDC-0449; (Erivance, Genentech)	Phase II	BCC, medulloblastoma, ovarian cancer, small-cell lung cancer, coloractal cancer (combined with cisplatin and etoposide), colorectal cancer (in combination with standard chemotherapy and bevacicumab), and upper gastrointestinal cancers (in combination with FOLFOLX chemotherapy)
BMS-833923; (Bristol-Myers Squibb and Exelixis)	Phase I	BCC, BCNS, small lung cancer (versus cisplatin and etoposide), inoperable, metastatic gastro, gastroesophageal or esophageal Adenocarcinoma (combined with cisplatin and carpecitabine), and multiple myeloma
IPI-926; Infinity Pharmaceuticals	Phase I	Advanced and/or metastatic solid tumour malignancies and metastatic pancreatic cancer (combined with gemcitabine)
LDE-225; (Novartis)	Phase I/II	Sporadic superficial and nodular skin BCC, BCNS, medulloblastoma; rhabdomyosarcoma neuroblastoma, hepatoblastoma, astrocytoma, advanced solid tumor cancers, and Medulloblastoma
PF-04449913; (Pfizer)	Phase I	select hematologic malignancies or with dasatinib in chronic myeloid leukemia (CML)